Navigation Links
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Date:9/8/2008

Liraglutide Liraglutide

1.2 mg + 1.8 mg + Placebo +

metformin + metformin + metformin +

rosiglitazone rosiglitazone rosiglitazone

N=178 N=178 N=177

Final HbA1c, %

Change HbA1c from 7.0 7.1 7.9

baseline % points -1.48* -1.48* -0.5

% HbA1c achieving

<7.0% 58* 54* 28

% HbA1c achieving

< or = 6.5% 36* 37* 14

Mean change in weight

from baseline, kg -1.02* -2.02 0.60

Mean change in

FPG from baseline,

mmol/L -2.2* -2.4* -0.4

Mean change in

PPG from baseline,

mmol/L -2.6 -2.7* -0.8

% reporting minor

hypoglycemic 9 8 5

events/subject/year 0.38 0.64* 0.17

Mean change in

systolic blood

pressure from

baseline, mmHg -6.7* -5.6* -1.1

*p<0.05 versus placebo

FPG, fasting plasma glucose; OAD, oral antidiabetic drug; PPG,

post-prandial glucose

Safety and tolerability of liraglutide

There were no major hypoglycemic episodes reported during the study. The rate of minor hypoglycemia (<3.1 mmol/L) was low in all groups (0.38, 0.64 and 0.17 events per subject year with liraglutide 1.2 mg, 1.8 mg and placebo, respectively). The most frequent adverse event was nausea, which was reported by 29-40% of patients treated with 1.2 mg and 1.8 mg respectively. However, nausea levels decreased to the same as the placebo group after the first 16 week
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... PRINCETON, N.J., Jan. 4, 2011 Pharmasset, Inc. (Nasdaq: ... 29th Annual J.P. Morgan Healthcare Conference to be held January ... CA. Schaefer Price, President and Chief Executive Officer, will provide ... at 9:00 AM (PT). To access a simultaneous ...
... Jan. 4, 2011 Boston Scientific Corporation (NYSE: ... M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article ... the American Medical Association .  The article reported on a ... received an implantable cardioverter defibrillator (ICD) did not meet evidence-based ...
Cached Medicine Technology:Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 3Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article 2
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where ... DNA signatures within the same cancer. Such differences ... treatment strategies. , Firstly they confirmed the mutual ... KRAS or BRAF mutation. Secondly, they found that ... have that specific mutation present uniformly throughout the ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... FDA-approved device has been shown to reduce seizures in ... percent. When coupled with an innovative electrode placement planning ... the complete elimination of seizures in nearly half of ... trials. , That,s good news for a large portion ... with epilepsy whose seizures can,t be controlled with medications ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... Researchers have discovered two common genetical variants that increase ... kidney disease is a condition in which kidneys of ... the correct fluid and waste balance that is part ... wastes in the body that can lead to toxicity ...
... have therapeutic properties that can be effective// against mental ... of the Universitat Autònoma de Barcelona in Spain have ... isolating a harmless part of the toxin called the ... from being transported by the synaptic membranes, and thus ...
... can ward off an attack of premenstrual syndrome// (PMS). ... symptoms that affect a lot of women a week ... of PMS are depression, feelings of aggression and mood ... social interactions and relationships are getting affected because of ...
... the graft to bypass a blockage in the blood// vessels ... graft to bypass blockages, scientists often use plastic prosthetic tubes. ... have dialysis. This is called a shunt. The problem with ... vessels, the blood flows twisting and turning as the artery ...
... weight may help themselves from the incidence of diabetes ... ,Diabetes affects the population in terms of affecting the ... insulin that helps in controlling the blood sugar levels. ... inactivity, genetic influence and age related factors. Recent studies ...
... has suggested that obesity,in middle age increases the ... a progressive,brain dysfunction that occurs most commonly late ... daily activities. ,The 27 year longitudinal study ... analyzed,prospective data from a population of around 10276,males ...
Cached Medicine News:
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... represents the latest breakthrough in visual ... the Humphrey Matrix will help you ... and assess treatment alternatives. Enhanced patient ... complete long-term glaucoma care for your ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... and disposable lens convenience for those with ... want crisp, clear vision with the convenience ... Vertex Toric lenses are manufactured using our ... a perfect edge on every lens. This ...
Medicine Products: